Enrichment of Circulating Tumor Cells of Lung Cancer and Correlation With Serum Leukomonocyte and Tumor Biomarkers: A Retrospective Study

Abstract

Study design Circulating tumor cells is important in the clinical diagnosis of cancer and there are a number of circulating tumor cell detection systems associated with different isolation strategies being validated. There is a novel platform, the CytoBot 2000, which utilizes a combination of physical and immunological technologies to isolate and capture circulating tumor cells. Methods In this retrospective study, 39 lung cancer patients and 11 normal healthy individuals were enrolled and performed circulating tumor cell tests and immunofluorescence staining with CytoBot 2000. The performance of this device was assessed by receiver operating characteristic curve. The clinical relevance of circulating tumor cells was assessed by Chi-square. The correlations between circulating tumor cell number and blood lymphocytes and tumor biomarkers were analyzed by Pearson correlation coefficient. Results The number of circulating tumor cell is significantly increased in lung cancer patients (3.74 > 0.45, P < .0001). The CytoBot 2000 presented a 100% (39/39) circulating tumor cell detection rate in lung cancer patients and 36% (4/11) in healthy individual blood samples, the sensitivity and specificity were 89.7% and 90.9%, respectively, and with the area under curve of 0.966. Further, there was a positive correlation between circulating tumor cell count and carcinoembryonic antigen 211 (R2 = 0.125, P = .027), but not blood lymphocytes ( P = .089). Conclusions This automatic platform showed excellent performance of circulating tumor cell detection by clinical sample. The tumor biomarkers increased with the number of circulating tumor cell in the lung cancer patients.

Prognosis value of circulating tumor cell PD‑L1 and baseline characteristics in patients with NSCLC treated with immune checkpoint inhibitors plus platinum‑containing drugs

“…The results revealed no significant association between CTC PD-L1 detection and IHC results, and the number of CTCs and CTC PD-L1 in the peripheral blood of patients was not significantly associated with either advanced cancer progression or PFS. A newly developed CTC separation device, CytoBot, was used in the present study, which was validated for the diagnosis of breast cancer ( 10 ) and lung cancer ( 11 ). However, the value of CytoBot in determining patient prognosis was not demonstrated in the present study.…”

“…In a previous study, CytoBot was used to detect CTCs in patients with advanced lung cancer, and the potential association between CTCs and other blood markers such as carcinoembryonic antigen (CEA) 211 and lymphocytes, was determined. Thus, the effectiveness of CytoBot has been initially validated ( 11 ). In the present study, the functionality of CytoBot was further determined through CTC PD-L1 detection, and the results were compared with tissue biopsies.…”